This Article Full Text Full Text (PDF) All Versions of this Article: 116/11/1267    most recent CIRCULATIONAHA.107.704254v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tanigawa, H. Articles by Rader, D. J. Search for Related Content PubMed PubMed Citation Articles by Tanigawa, H. Articles by Rader, D. J. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Hazardous Substances DB CHOLESTEROL Related Collections Animal models of human disease Pathophysiology Genetically altered mice Gene therapy Lipid and lipoprotein metabolism

(Circulation. 2007;116:1267-1273.)
© 2007 American Heart Association, Inc.

Molecular Cardiology

Expression of Cholesteryl Ester Transfer Protein in Mice Promotes Macrophage Reverse Cholesterol Transport

Hiroyuki Tanigawa, MD, PhD; Jeffrey T. Billheimer, PhD; Jun-ichiro Tohyama, MD; YuZhen Zhang, MD, PhD; George Rothblat, PhD; Daniel J. Rader, MD

From the Institute for Translational Medicine and Therapeutics and the Cardiovascular Institute (H.T., J.T.B., J.-i.T., Y.Z.Z., D.J.R.), University of Pennsylvania School of Medicine, Philadelphia, and the Children’s Hospital of Philadelphia (G.R.), Pa.

Correspondence to Daniel J. Rader, MD, University of Pennsylvania Medical Center, 654 Biomedical Research Building II/III, 421 Curie Blvd, Philadelphia, PA 19104. E-mail rader{at}mail.med.upenn.edu

Received March 21, 2007; accepted June 29, 2007.

Background— Cholesteryl ester transfer protein (CETP) transfers cholesteryl esters from high-density lipoproteins to apolipoprotein (apo) B–containing lipoproteins and in humans plays an important role in lipoprotein metabolism. However, the role that CETP plays in mediation of reverse cholesterol transport (RCT) remains unclear. We used a validated in vivo assay of macrophage RCT to test the effect of CETP expression in mice (which naturally lack CETP) on macrophage RCT, including in mice that lack the low-density lipoprotein receptor or the scavenger receptor class B, type I.

Method and Results— A vector based on adeno-associated virus serotype 8 (AAV8) with a liver-specific thyroglobulin promoter was used to stably express human CETP in livers of mice and was compared with an AAV8-lacZ control vector. The RCT assay was performed 4 weeks after vector injection and involved the intraperitoneal injection of acetylated low-density lipoprotein cholesterol–loaded and ³H-cholesterol–labeled J774 macrophages in mice with plasma sampling at several time points, liver and bile sampling at 48 hours, and continuous fecal collection to measure ³H-sterol as an integrated readout of macrophage RCT. In apobec-1–null mice, CETP expression reduced plasma high-density lipoprotein cholesterol levels but significantly increased fecal ³H-sterol excretion. In low-density lipoprotein receptor/apobec-1 double-null mice, CETP expression reduced high-density lipoprotein cholesterol levels and had no effect on fecal ³H-sterol excretion. Finally, in scavenger receptor class B, type I–null mice, CETP expression reduced high-density lipoprotein cholesterol levels and significantly increased fecal ³H-sterol excretion.

Conclusion— The present results demonstrate that CETP expression promotes macrophage RCT in mice, that this effect is dependent on the low-density lipoprotein receptor, and that CETP expression restores to normal the impaired RCT in mice deficient in scavenger receptor class B, type I.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				D. Masson, M. Koseki, M. Ishibashi, C. J. Larson, S. G. Miller, B. D. King, and A. R. Tall Increased HDL Cholesterol and ApoA-I in Humans and Mice Treated With a Novel SR-BI Inhibitor Arterioscler Thromb Vasc Biol, December 1, 2009; 29(12): 2054 - 2060. [Abstract] [Full Text] [PDF]

				H. Tanigawa, J. T. Billheimer, J.-i. Tohyama, I. V. Fuki, D. S. Ng, G. H. Rothblat, and D. J. Rader Lecithin: Cholesterol Acyltransferase Expression Has Minimal Effects on Macrophage Reverse Cholesterol Transport In Vivo Circulation, July 14, 2009; 120(2): 160 - 169. [Abstract] [Full Text] [PDF]

				I. Tancevski, A. Wehinger, E. Demetz, J. Hoefer, P. Eller, E. Huber, U. Stanzl, K. Duwensee, K. Auer, W. Schgoer, et al. The thyromimetic T-0681 protects from atherosclerosis J. Lipid Res., May 1, 2009; 50(5): 938 - 944. [Abstract] [Full Text] [PDF]

				D. J. Rader, E. T. Alexander, G. L. Weibel, J. Billheimer, and G. H. Rothblat The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis J. Lipid Res., April 1, 2009; 50(Supplement): S189 - S194. [Abstract] [Full Text] [PDF]

				F. C. McGillicuddy, M. de la Llera Moya, C. C. Hinkle, M. R. Joshi, E. H. Chiquoine, J. T. Billheimer, G. H. Rothblat, and M. P. Reilly Inflammation Impairs Reverse Cholesterol Transport In Vivo Circulation, March 3, 2009; 119(8): 1135 - 1145. [Abstract] [Full Text] [PDF]

				W. R. Lagor, R. J. Brown, S.-A. Toh, J. S. Millar, I. V. Fuki, M. de la Llera-Moya, T. Yuen, G. Rothblat, J. T. Billheimer, and D. J. Rader Overexpression of Apolipoprotein F Reduces HDL Cholesterol Levels In Vivo Arterioscler Thromb Vasc Biol, January 1, 2009; 29(1): 40 - 46. [Abstract] [Full Text] [PDF]

				J. J. Regieli, J. W. Jukema, D. E. Grobbee, J. J.P. Kastelein, J. A. Kuivenhoven, A. H. Zwinderman, Y. van der Graaf, M. L. Bots, and P. A. Doevendans CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction Eur. Heart J., November 2, 2008; 29(22): 2792 - 2799. [Abstract] [Full Text] [PDF]

				E. M. deGoma, R. L. deGoma, and D. J. Rader Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2199 - 2211. [Abstract] [Full Text] [PDF]

				U. Tchoua, W. D'Souza, N. Mukhamedova, D. Blum, E. Niesor, J. Mizrahi, C. Maugeais, and D. Sviridov The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport Cardiovasc Res, March 1, 2008; 77(4): 732 - 739. [Abstract] [Full Text] [PDF]

				M. Lee-Rueckert, R. Vikstedt, J. Metso, M. Jauhiainen, and P. T. Kovanen Association of cholesteryl ester transfer protein with HDL particles reduces its proteolytic inactivation by mast cell chymase J. Lipid Res., February 1, 2008; 49(2): 358 - 368. [Abstract] [Full Text] [PDF]

				D. J. Rader Illuminating HDL -- Is It Still a Viable Therapeutic Target? N. Engl. J. Med., November 22, 2007; 357(21): 2180 - 2183. [Full Text] [PDF]

				M. Cuchel and D. J. Rader Is the Cholesteryl Ester Transfer Protein Proatherogenic or Antiatherogenic in Humans? J. Am. Coll. Cardiol., November 13, 2007; 50(20): 1956 - 1958. [Full Text] [PDF]